| Document |
Document Title |
|
WO/2022/102992A1 |
The present invention provides a novel compound and an organic light-emitting device using same.
|
|
WO/2022/103960A1 |
Described herein are HSD17B13 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of liver disease, metabolic disease, or cardiovascular disease, such...
|
|
WO/2022/095461A1 |
Disclosed are a compound for specifically enhancing the spatial coupling degree of a TRPV4-KCa2.3 complex and the use thereof, which belong to the field of chemical medicines. The compound, which has a structure of general formula (I), m...
|
|
WO/2022/098809A1 |
Compounds of the formula I: or the pharmaceutically acceptable salts thereof, are inhibitors of haematopoietic progenitor kinase 1 (HPK1) useful in the treatment of diseases or disorders associated with HPK1. Also disclosed herein are us...
|
|
WO/2022/098170A1 |
The present invention relates to a series of novel phenylaminopyridine derivatives and a use thereof for inhibiting capsid assembly and for preventing or treating virus infectious diseases thereby.
|
|
WO/2022/098806A1 |
Compounds of the following formula (I); or the pharmaceutically acceptable salts thereof, are inhibitors of haematopoietic progenitor kinase 1 (HPK1) useful in the treatment of diseases or disorders associated with HPK1. Also disclosed h...
|
|
WO/2022/089589A1 |
A flavonoid glycoside-organoamine DPP-4 inhibitor double salt. The flavonoid glycoside has the structural formula as shown in formula (1), wherein R1-R9 are independently selected from a group consisting of -H, -OH, C1-C6 alkyl, alkoxy o...
|
|
WO/2022/091091A1 |
The present invention relates to polymers comprising bifunctional mono- or polycyclic heterocyclic or heteroaromatic repeating units having disinfecting activity, compositions thereof, and methods for disinfecting surfaces utilizing said...
|
|
WO/2022/093849A1 |
Provided is a compound of Formula (I) or a pharmaceutically acceptable salt thereof, that is a modulator of 5-HT2A and can be used in treating diseases and disorders associated with 5-HT2A serotonin receptor expression and/or activity. T...
|
|
WO/2022/087763A1 |
Provided in the present invention are a cocrystal containing a sorafenib free base and 5-fluorouracil, a pharmaceutical composition, and uses thereof. The cocrystal comprises: the sorafenib free base; and 5-fluorouracil. The cocrystal of...
|
|
WO/2022/090101A1 |
The invention is directed to the commercially synthetic process of 2,4-Dichloro-5-amino- pyrimidine, starting from 5-nitrouracil.
|
|
WO/2022/084334A1 |
The present invention relates to compositions comprising as component (A) at least one compound of formula (I), or an agrochemically acceptable salt thereof wherein R1 is (II) or (III) and, as component (B), at least one compound, or agr...
|
|
WO/2022/083679A1 |
Provided are prodrugs for sustained releasing therapeutic agents, and methods for using such prodrugs for the treatment of diseases.
|
|
WO/2022/083657A1 |
The present invention relates to a substituted benzo or pyridopyrimidine amine inhibitor, a preparation method therefor, and an application thereof. Specifically, a compound of the present invention is of a structure as shown in formula ...
|
|
WO/2022/086892A1 |
The invention relates to novel heterocyclic compounds and pharmaceutical preparations thereof. The invention further relates to methods of treating or preventing cancer using the novel heterocyclic compounds of the invention.
|
|
WO/2022/083476A1 |
Provided are a new crystal form of Gefapixant (referred to as "compound I") citrate and a preparation method therefor, a pharmaceutical composition containing the crystal form, and a use of the crystal form in the preparation of P2X3 rec...
|
|
WO/2022/082646A1 |
A light-emitting element, comprising a hole blocking layer comprising one or more of the compounds represented by formulas (1)a and (1)b below. Z1-Z11 are selected from H or R. R, R1 and R2 are selected from deuterium, halogen, cyano, ni...
|
|
WO/2022/087624A1 |
The present disclosure relates generally to compounds and compositions thereof for inhibition of RAS, such as KRAS, HRAS and NRAS, including mutant forms of KRAS, HRAS and NRAS, particularly those harboring a G12C mutation, methods of pr...
|
|
WO/2022/079226A1 |
The present invention relates to compounds which show activity as PDEdelta/PDE6D Inhibitors and pharmaceutical compositions comprising these compounds, their use in medicine as well as their use in the treatment of cancer.
|
|
WO/2022/078305A1 |
A compound represented by general formula (I) or a stereoisomer, tautomer, deuterated substance, solvate, prodrug, metabolite, pharmaceutically acceptable salt or co-crystal thereof, an intermediate thereof, and a preparation method ther...
|
|
WO/2022/081872A1 |
Compounds are provided having the structure of Formula (I): or a pharmaceutically acceptable salt, solvate, hydrate, isomer, tautomer, racemate, or isotope thereof, wherein X, Q, Ak, L1, L2, R1, R2, R3 and n are as defined herein. Also p...
|
|
WO/2015/136292A9 |
The invention relates to a DDX3X inhibitorfor use in the treatment of pneumovirus infection in a mammal, wherein the DDX3X inhibitor may be a compound of Formula (I) wherein y, Z, R1, X, L, Ra and Rb are as defined herein. The invention ...
|
|
WO/2022/076973A1 |
The present disclosure relates to compounds and compositions for inhibition of Bcr-Abl tyrosine kinases, methods of preparing said compounds and compositions, and their use in the treatment of various cancers, such as chronic myeloid leu...
|
|
WO/2022/076975A1 |
The present disclosure relates to compounds and compositions for inhibition of Bcr- Abl tyrosine kinases, methods of preparing said compounds and compositions, and their use in the treatment of various cancers, such as chronic myeloid le...
|
|
WO/2022/076627A1 |
This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) having the core structure:, pharmaceutical compositions containing at least one such modulator, methods of treating CFTR mediated diseases,...
|
|
WO/2022/074143A1 |
The invention provides compounds of formula (IA) and compounds of formula (IB) and pharmaceutically acceptable salts thereof; wherein A is selected from group (A1) and group (A2): wherein #1 is attached to the carbon atom forming the oxi...
|
|
WO/2022/076629A1 |
This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) having the structure: (I), pharmaceutical compositions, containing at least one such modulator, methods of treatment of cystic fibrosis usi...
|
|
WO/2022/073424A1 |
Provided in the present invention are a small molecule compound, which is the compound represented by formula (I), or a stereoisomer, a geometric isomer, a tautomer, a hydrate, a solvate, and a pharmaceutically acceptable salt or a prodr...
|
|
WO/2022/067094A1 |
Methods are provided for modulating MRGPR X2 generally, or for treating a MRGPR X2 or a MRGPR X2 ortholog dependent condition, more specifically, by contacting the MRGPR X2 or the MRGPR X2 ortholog by administering to a subject in need t...
|
|
WO/2022/063229A1 |
Provided are a salt of an arylaminoquinazoline-containing compound as shown in formula 2, a solvate or hydrate thereof, a preparation method therefor and the use thereof. The prepared salt has good crystallinity, and compared to a compou...
|
|
WO/2022/063106A1 |
Provided are novel pharmaceutically active compounds and their preparation methods. The compounds inhibit mutant EGFR and are useful in the treatment of oncological diseases.
|
|
WO/2022/062356A1 |
A medicine for treating or preventing diseases related to the activity of an LRRK2 kinase or an abnormal LRRK2 mutant kinase, which belongs to the field of medicine. The medicine comprises at least one of a compound represented by chemic...
|
|
WO/2022/066545A1 |
A method of chemovaccination against Plasmodium infections comprising administering to a patient, an effective amount of a dual inhibitor of plasmepsin IX and X, or a pharmaceutically acceptable salt thereof.
|
|
WO/2022/061140A1 |
Aryl hydrocarbon receptor (AHR) agonists and their use in treating or preventing or reducing the risk of an inflammatory disorder associated with a reduced expression of an aryl hydrocarbon receptor (AHR), including necrotizing enterocol...
|
|
WO/2022/061202A1 |
The present disclosure relates to compounds that are capable penetrating to the blood brain barrier to modulate the activity of EGFR tyrosine kinase. The disclosure further relates to methods of treating glioblastoma and other EGFR media...
|
|
WO/2022/060945A1 |
The present disclosure encompasses solid state forms of Gefapixant, in embodiments crystalline polymorphs or salts or co-crystals of Gefapixant, processes for preparation thereof, and pharmaceutical compositions thereof.
|
|
WO/2022/061348A1 |
Provided herein are SOS1 protein degraders, for example, a compound of Formula (I), and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of ...
|
|
WO/2022/059996A1 |
The present invention relates to a blood circulation micro in-vitro corpuscle-mediated cancer treatment composition and, more specifically, to a composition for preventing or treating cancer comprising a compound represented by chemical ...
|
|
WO/2022/053541A1 |
The present invention relates to new compounds having appetite-suppressing effects and their uses as a drug for treating diseases and disorders, especially metabolite syndrome.
|
|
WO/2022/055721A1 |
Certain molecular characteristics of cancer cells or tumors can be indicative of their sensitivity to various combination therapies. The cancer cells or tumors exhibiting such molecular profiles, such as upregulation of genes associated ...
|
|
WO/2022/053823A1 |
The present invention provides compounds of formula (I) and pharmaceutically acceptable salts, solvates and prodrugs thereof wherein m, R1, R2, R3, L and X are as defined in the specification, processes for their preparation, pharmaceuti...
|
|
WO/2022/053422A1 |
The present invention relates to compounds of Formula (I), or an agronomically acceptable salt of said compounds wherein X1, Y1, Y2, Z1, Z2, R1, R2, R5, R6, R9 and n are as defined herein. The invention further relates to herbicidal comp...
|
|
WO/2022/051337A1 |
The present invention is directed to certain 2-aminoquinzaoline derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R3, R4,X1, and X2 are as defined herein, which are potent inhibitors of LRRK2 kinase a...
|
|
WO/2022/051565A1 |
The invention provides substituted 4-piperidinyl-quinazolines, 4-piperidinyl-pyrimidine-2-amines, and related compounds, pharmaceutical compositions, their use for inhibiting ERK5 activity, and their use in the treatment of medical disor...
|
|
WO/2022/043923A1 |
A method for the synthesis of a compound of Formula (II) is provided. Also disclosed is the salt form of the compound. The method includes the introduction of a piperidinyl moiety in a polar aprotic solvent system, followed by the remova...
|
|
WO/2022/046999A1 |
Provided herein are compounds that inhibit the function of MYB. In particular, provided are compounds that can inhibit MYB and/or disrupt the interaction between MYB and a protein associated with MYB, a protein whose dysregulation is imp...
|
|
WO/2022/046779A1 |
Provided herein are polymorphs of (2E)-3-fluoro-2-({[2-( 4-methoxypiperidin- 1 - yl)pyrimidin-5-yl]oxy}methyl)prop-2-en-1-aminium 4-methylbenzenesulfonate, compositions thereof, methods of preparation thereof, and methods of use thereof.
|
|
WO/2022/043205A1 |
The present invention relates to substituted N-phenyluracils of general formula (I) or salts thereof, wherein the radicals in general formula (I) correspond to the definitions given in the description, and to the use thereof as herbicide...
|
|
WO/2022/042267A1 |
The present application relates to the field of organic light-emitting materials, and provides a nitrogen-containing compound, an electronic component, and an electronic device. The structure of the nitrogen-containing compound is repres...
|
|
WO/2022/040747A1 |
The present invention relates to compounds that have zinc and/or iron ionophore activity and their use in treating diseases that are modulated by reducing zinc and/or iron. In particular embodiments, the compounds are compounds of formul...
|
